EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.

Abstract excerpt

Mutations involving the TP53 gene are frequently identified in up to 50% of all human tumors, including glioblastomas. Analysis of expression patterns of TP53 in glioblastomas shows that it is mainly mutated in secondary glioblastomas and is less common in primary GBMs. However, the prognostic significance of TP53 loss of function in astrocytomas has always been controversial. In contrast, EGFR/erbB2 complexes...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Cycle
• Share to Central Nervous System Neoplasms
• Share to G2 Phase